# A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)

NCT06507748

| | |
|---|---|
| **Status** | RECRUITING |
| **Phase** | Not Applicable |
| **Sponsor** | National Cancer Institute (NCI) |
| **Enrollment** | 70 participants |

## Key Eligibility Criteria

### Inclusion (6)

- History of clinical or genetic diagnosis of NF1 as per the 2021 revised diagnostic criteria
- Age \>= 1 year
- At least one digit (finger or toe) without open wounds for application of the device
- Individuals must understand English or Spanish
- Individuals who are \< 18 years must have a caregiver willing to help the child engage in study procedures, assist with fitting the AlgometRx Nociometer (Registered Trademark) device, and complete the observer reported (ObsRO) measures. Note: the caregiver of a child participant \>= 5 years old must be able to understand English or Spanish, the caregiver of a child participant 1-4 years old must be able to understand English (to help complete the observational pain measure for the younger children that is only available in English)

... and 1 more (see full listing online)

### Exclusion (3)

- History of eye pathology which precludes pupillometry, such as problems with pupillary reflex, blindness or inability to open at least one eye fully for evaluation
- Individuals with chronic use of medication that specifically affects their pupillary response, such as atropine-containing eye drops
- Uncontrolled intercurrent illness evaluated by medical history that would potentially increase in risk of participant

## Locations (2 total)

Children's National Medical Center, Washington D.C., District of Columbia, United States
National Institutes of Health Clinical Center, Bethesda, Maryland, United States